Coronavirus | Glenmark’s antiviral drug Fabiflu to be used for patients with mild and moderate symptoms

The drug has been approved under emergency category and needs an undertaking from the patient.

June 20, 2020 02:05 pm | Updated 02:09 pm IST - Mumbai

Representational Image

Representational Image

Glenmark Pharmaceuticals had on Friday received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19 .

FabiFlu will be used for treating COVID-19 patients with mild to moderate symptoms and will be made available from today evening and by next week across the country. The company has got approval under emergency category.

Each tablet of 200 mg costs ₹103 and a strip containing 34 tablets has been priced at ₹3500. It will be made available at hospitals and chemist shops and will be sold under medical presciption.

On the first day, a patient will be administered 1800 mg twice each. From the second day, the patient will be given 800 mg twice a day for upto 14 days as per the doctor’s advice. The medicine can be administered to patients between the age group of 18 and 75.

Since the approval is under emergency category due to the pandemic, the patient has to give an undertaking before consuming the medicine.

70 to 80% of Covid-19 patients are from the mild and medium category for which the drug has been approved. A patient of this type need not be admitted to the hospital and can stay at home.

Glenmark is taking care of end to end processes of this medication starting from manufacturing API and development of formulation to manufacturing as well as marketing and supply. Company executives said this will help in reducing the pressure on hospitals.

Clinical trial is on for 150 patients in India. For the next stage, the company is planning for a combination trial for Covid-19 treatment.

Once administered the drug will help in bringing down the viral load on the patient, company executives said.

Glenmark is the first company to come out with an oral antiviral drug for mild and moderate Covid-19 treatment.

Favipiravir has been used in Russia, Japan and China to treat such patients and has been proved successful.

At the moment the drug will be under restricted use, which means it can be consumed only under doctor’s guidance and supervision. People without prescription cannot buy it.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in


Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.